T1	Participants 144 234	patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
T2	Participants 413 532	patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy
T3	Participants 590 623	patients with active RA (n = 507)
